entertainment -WSS

entertainment

author：comprehensive 2025-08-12 10:17:04 - browse：2

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： American TikTok star stuck in Dubai for months following rental car altercation

Wikipedia

WSS

Eyeing GLP

Trump team launching legal defense fund to help pay legal bills

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Teacher posts viral 'school supply rant' with advice for parents

Eyeing GLP

FDA poised to publish guidelines for clinical trial diversity

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

5 wounded, 2 critically, in Michigan shopping center shooting

How to save PrEP access — and even expand it

Listen: More tumult at BIO & coercive care for sickle cell patients

Heart attack and stroke risk calculators need revising

5 wounded, 2 critically, in Michigan shopping center shooting

After affirmative action ruling, medical educators look to 'holistic review'

Campaign finance charge dropped from case against Sam Bankman

Drug repurposing or repositioning? The language matters

Addressing health care workers' trauma can help fight burnout

Wikipedia

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Scrutiny of post

Cue Health, Covid

leisure time

Wikipedia

Wikipedia

knowledge